In episode 321, James and Mike discuss two interesting studies. One is on the duration of antibiotics for community-acquired pneumonia and the other about the impact of total knee replacement on the overall quality of life. Interestingly, the results of these studies were different although that may have been the fact that one was on pneumonia and the other on TKR.

Show notes

1) Duration of Antibiotic Treatment
in Community-Acquired Pneumonia
A Multicenter Randomized Clinical Trial

JAMA Intern Med. doi:10.1001/jamainternmed.2016.3633

2) A Randomized, Controlled Trial of Total Knee Replacement 

N Engl J Med 2015;373:1597-606

In episode 320, Mike and James PREMIUM out yet again and talk about 3 new diabetes publications that our listeners have asked us about.

Show notes

1) LEADER Study

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

N Engl J Med 2016; 375:311-22

2) Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

N Engl J Med 2015; 373:2247-57

3) Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care

BMJ 2016;354:i3477

In episode 319, Mike and James begin questioning the number of questions they are having to answer but plough forward and talk about confidence intervals, anticoagulation bridging, hormone replacement and finally bring it all home with comments on DRE. 

Show notes

How confidence intervals become confusion intervals

BMC Medical Research Methodology 2013;13:134

In episode 318, Mike and James attempt to answer even more questions. We run the spectrum from steroid injections, to repeat bone density measurements, to vortioxetine, generic drugs, and sitagliptin. Bottom line – please stop going to industry sponsored CME.

Show notes

1) Generic drugs

Tools for Practice

2) My Studies

mystudies.org

In episode 317, James and Mike continue with their question and answering quest. We offer our spin on cardiovascular risk assessment, prostate screening, creatinine clearance and at the end leave our listeners questioning our podcast.

Show notes

1) Bridge Over Diagnosis – a parody of Bridge Over Troubled Water

2) Estimating Renal Function for Drug Dosing: Rewriting the Gospel?

CJHP 2008;2:138-43

3) Kidney calc

In episode 316, James and Mike finally get to the back-log of listener questions. We talk about stats, risk factors, guidelines and of course what podcast wouldn’t be complete without mentioning statins. 

Show notes

1) Critical appraisal by and for dummies – three podcast episodes

PART 1

PART 2

PART 3

2) How to critically appraise an RCT in 10 minutes

iBook 

pdf version

3) Guidelines for treating risk factors should include tools for shared decision making 

BMJ 2016; 353 doi: http://dx.doi.org/10.1136/bmj.i3147

In episode 315, James, Mike and Peter Loewen finish talking about the whole issue of antidotes for anticoagulants. In this podcast we focus on how we can have the conversation about these products with patients to allow for as much as possible, shared decision-making.

Show notes

Slides from Peter Loewen’s talk

Antidotes for Anticoagulants “Take The Money And Run”?

SPARC – Stroke Prevention in Atrial Fibrillation Risk Tool

In episode 314, James and Mike welcome Peter Loewen back to the podcast to help us think through how we should frame the whole issue around antidotes for anticoagulants. At the end, we realise it is much more than just do we or do we not have an antidote.

Show notes

Slides from Peter Loewen’s talk

Antidotes for Anticoagulants “Take The Money And Run”?

SPARC – Stroke Prevention in Atrial Fibrillation Risk Tool

In episode 313, James and Mike go over two new large COPD trials that looked at the use of different types of inhalers and find that unfortunately they do very little to clinically relevant outcomes. The bottom line is don’t smoke.

Show notes

1) SUMMIT trial – Fluticasone furoate and vilanterol

Lancet 2016;387:1817-26

2) FLAME trial – Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD 

NEJM 2016 DOI: 10.1056/NEJMoa1516385 

In episode 312, Mike and James give you PREMIUM information on high dose Vit D, delayed antibiotics, spironolactone and pioglitazone. All this new evidence supports pretty much all the premium stuff we’ve been saying for years – thank goodness.

Show notes

1) Vitamin D

JAMA Intern Med 2016;176:175-83

2) Delayed antibiotics

JAMA Intern Med 2016;176:21-9

3) Spironolactone

Lancet 2015;386:2059-68

4) Pioglitazone

N Engl J Med 2016;374:1321-31